IBD: Ulcerative Colitis
Biosimilars for IBD: Making the Transition Webinar
On May 28th, Dr. McCurdy answered the following questions in a very informative webinar presentation on Biosimilars:
- What’s the difference between a reference biologic drug and a biosimilar?
- Biosimilars: What’s Health Canada saying?
- What is the clinical evidence to date?
- How do doctors go about transitioning their patients from a reference biologic drug to a biosimilar?
Watch this webinar now!
Related Articles
Helping inflammatory bowel disease (IBD) patients best understand transitioning/switching from a reference biologic to a biosimilar.
